Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Computer-Guided statin dosing shows promise for liver patients

NCT ID NCT07459972

Knowledge-focused Sponsor: Kafrelsheikh University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a computer program could help doctors choose the right dose of simvastatin for people with cirrhosis and high blood pressure in the liver. Twenty-two patients received either 5 mg or 15 mg of simvastatin daily for three months. Researchers measured changes in liver blood flow and checked for side effects to see if the computer-guided dosing was safe and effective.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Simvastatin
What this could lead to
If successful, this approach could help doctors personalize statin doses for people with liver disease, potentially reducing complications from high blood pressure in the liver.
What could go wrong
This was a small pilot study with only 22 participants, so results may not apply to everyone. The study focused on short-term safety and blood flow changes, not long-term outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

22 people

The number who actually took part.

Started

Mar 2024

Finished

Jun 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients aged ≥ 18 years * Confirmed diagnosis of liver cirrhosis (clinical, laboratory, or imaging evidence) * Evidence of portal hypertension (clinical findings and/or Doppler ultrasound measurements) * No previous history of variceal bleeding * Child-Pugh class A or B Exclusion Criteria: * Active hepatocellular carcinoma * Severe renal impairment (eGFR \< 30 mL/min/1.73 m²) * Baseline creatine kinase (CK) \> 3 × upper limit of normal * Known hypersensitivity to simvastatin * Current therapy with strong CYP3A4 inhibitors * Any active malignancy in the last 2 years * Pregnancy or lactation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Liver cirrhosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cirrhosis of liver portal hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Liver cirrhosis Portal hypertension related to cirrhosis

Contacts and locations

Locations

  • Kafrelsheikh University

    Cairo, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.